Cipla and Stempeutics collaborate for Stempeucel, to treat Critical Limb Ischemia (CLI)

▴ cipla-and-stempeutics-collaborate-to-treat-critical-limb-ischemia-cli
First approved allogeneic cell therapy product globally for the treatment of CLI

Cipla Limited referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.

The product has been developed by Stempeutics over a period of twelve years. The company's proprietary pooling approach provides for an efficient manufacturing process thereby enabling the product to be made accessible to patients at an affordable cost. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients. The proprietary technology also helps Stempeucel extend the therapeutic potential of the drug across multiple disease categories. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.

CLI is a progressive form of peripheral arterial disease that is caused by severe blockage in the arteries thereby reducing blood flow. This may result in the development of sores and wounds in legs and feet with a high risk of limb amputation. It is estimated that about 5 million patients in India are impacted by this debilitating disease. With the current contemporary vascular techniques, it is estimated only 25% of patients can be managed with satisfactory clinical outcomes.

Stempeucel is a breakthrough treatment which is designed to enhance the body's limited capability to restore blood flow in ischemic tissue. It is derived from allogeneic pooled mesenchymal stromal cells isolated from the bone marrow of healthy, adult voluntary donors. It directly addresses the root cause of the disease by reducing inflammation, stimulating growth of collateral blood vessels and repairing damaged muscle, thereby reducing the pain, healing the ulcers and salvaging the affected limb. The drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers.

Currently, Stempeutics is working on a strategy for other international markets including US, EU and Japan. The global critical limb ischemia treatment market expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2020 and 2025.

Commenting on the DCGI approval, Mr. Manohar BN, MD & CEO of Stempeutics, said, "Obtaining DCGI approval for Stempeucel is an important and historic milestone for Stempeutics. It is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores our global leadership in allogeneic, pooled MSC technology. We believe that the Stempeucel product is a game-changer, offering an advanced therapeutic treatment for millions of patients suffering from this dreadful disease."

Mr. Umang Vohra, Managing Director and Global CEO of Cipla, said, "Our focus on innovation is guided by our strong sense of responsibility to address unmet patient needs and alleviate suffering. We are pleased to see that our decade-long partnership with Stempeutics has achieved a significant milestone. CLI is a serious and painful condition that impacts patients worldwide and we are happy that we are able to introduce this stem cell therapy in the country at an affordable cost."

Dr Pawan Kumar Gupta, Senior VP, Medical & Regulatory Affairs, Stempeutics, said, "We are excited to receive this marketing approval from DCGI for this very important indication. In CLI, fatty deposits block arteries in the leg, leading to greatly reduced blood flow, pain at rest, non-healing ulcers, and gangrene. Patients with CLI are at an immediate risk for limb amputation and death. Now Stempeucel® provides hope for a new, effective treatment and a better quality of life for such CLI patients. Also, Stempeutics is committed to advancing its peripheral artery disease programs in CLI to other parts of the World."

Tags : #CIPLA #Stempeutics #BreakthroughinCli #CriticalLimbIschemia #LatestPharmaUpdateAug21 #LatestPharmaNewsAug21

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

375 Cyclists Gear Up for Health and Fitness at Asian Hospital’s 21KM and 10KM Cycling MarathonMarch 17, 2025
Trapped in the Dopamine Loop: Why You Can’t Stop Scrolling, Eating, or ShoppingMarch 17, 2025
Pig Kidney Transplant Shakes the Medical World: Is This the Future of Organ Donation?March 17, 2025
ENO celebrates Cricket banter in a witty new campaign featuring Aakash GuptaMarch 17, 2025
Advancing Healthcare with Innovation: A Life-Saving Success StoryMarch 17, 2025
MVP Group’s startup accelerator arm IdeaSpace appoints Alwyn Rosel as new Executive Director, succeeds Jay FajardoMarch 17, 2025
SRM Global Hospitals Hosts SPACE 2025 to Advance Electrophysiology and Arrhythmia Treatment in IndiaMarch 17, 2025
The Sleep Crisis in India: Why Rest is Becoming a LuxuryMarch 17, 2025
Managing High Blood Pressure: Importance for Kidney HealthMarch 15, 2025
Teenagers Are Losing Friends While Chasing Perfection: Here’s WhyMarch 13, 2025
Your Desk Job is Destroying Your Mind: Here’s How to Fight BackMarch 13, 2025
Wow! Momo Disrupts FMCG Cup Noodles Market with 'Desi-Asian Flavours' – A First in IndiaMarch 13, 2025
How India’s Kidney Health Crisis is Growing UnnoticedMarch 13, 2025
Stuck Between the Snooze Button and the Hustle: Entrepreneurs Struggle to Get Quality SleepMarch 13, 2025
Can Coffee Keep You Steady on Your Feet? New Study Reveals the TruthMarch 13, 2025
NephroPlus Sets Guinness World Record & India Book of Records Title for Largest Kidney Health Screening DriveMarch 12, 2025
India Choosing to Eat Healthy; Order Volumes Up by 60% for Nutritional ProductsMarch 12, 2025
Amrita students win first prize at DecodeX 2025 hackathonMarch 12, 2025
Why Millions Are Losing Their Sight to Glaucoma And How You Can Prevent ItMarch 12, 2025
Çelebi India Ranks 3rd Worldwide in Ground Handling Performance for Turkish CargoMarch 12, 2025